Clinical Trial

A Trial Comparing SHR-1139 Injection With Placebo in Patients With Moderate-to-severe Plaque Psoriasis

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 14, 2025 (before its estimated November 2025 completion). Its status may not reflect the trial's current state.
Summary
The objective of this study is to evaluate the efficacy, safety, pharmacokinetics (PK) and immunogenicity of SHR-1139 injection in patients with moderate to severe plaque psoriasis.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-09.
Status change: Not Yet Recruiting → Active, Not Recruiting 2025-07-10
Trial Details
NCT Number NCT06875934
Lead Sponsor Guangdong Hengrui Pharmaceutical Co., Ltd
Conditions Moderate to Severe Plaque Psoriasis
Enrollment 145 participants
Start Date 2025-03-28
Primary Completion 2025-11 (estimated)
Study Completion 2026-10 (estimated)
Updated on ClinicalTrials.gov 2025-07-14